The Society of Thoracic Surgeons Intermacs Database Annual Report: Evolving Indications, Outcomes, and Scientific Partnerships.
CONCLUSIONS: With the evolution of MCS, patient phenotype and outcomes are also changing over time. CF LVAD support is increasingly being used in the less ill patient phenotype and more patients are supported for destination therapy. Mean survival is now approaching 5 years, but adverse events, especially neurologic events, continue to have a detrimental impact on the success of CF LVAD support.
PMID: 30691584 [PubMed - in process]
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Kormos RL, Cowger J, Pagani FD, Teuteberg JJ, Goldstein DJ, Jacobs JP, Higgins RS, Stevenson LW, Stehlik J, Atluri P, Grady KL, Kirklin JK Tags: Ann Thorac Surg Source Type: research
More News: Bleeding | Brain | Cardiogenic Shock | Cardiology | Cardiovascular & Thoracic Surgery | Databases & Libraries | Gastroenterology | Heart | Heart Failure | Heart Transplant | Lung Transplant | Medicaid | Medicare | Neurology | Neuroscience | Neurosurgery | Science | Stroke | Transplants